Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$8.28 -1.8%	$5.81	$1.76 ▼ $8.56	$751.46M	-0.49	1.15 million shs	1.32 million shs
AVBP ArriVent BioPharma	$22.72 +3.7%	$21.86	$15.47 ▼ $36.37	$749.26M	1.2	233,692 shs	272,035 shs
IMTX Immatics	$6.21 +1.3%	$5.54	$3.30 ▼ $13.09	$745.10M	0.81	681,619 shs	311,204 shs
VYGR Voyager Therapeutics	$3.22 -1.5%	$3.19	$2.65 ▼ $9.55	$180.95M	0.85	489,821 shs	381,534 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-1.78%	+12.04%	+55.35%	+108.04%	+290.57%
AVBP ArriVent BioPharma	+3.74%	+3.13%	-9.05%	+25.25%	+15.62%
IMTX Immatics	+1.31%	+3.50%	+1.14%	+45.77%	-49.47%
VYGR Voyager Therapeutics	-1.53%	-9.30%	+3.21%	+1.90%	-63.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	3.4059 of 5 stars	4.5	1.0	0.0	3.2	2.5	0.6
AVBP ArriVent BioPharma	2.3073 of 5 stars	4.6	0.0	0.0	2.9	0.8	0.0
IMTX Immatics	3.1048 of 5 stars	3.6	4.0	0.0	3.7	1.7	0.0
VYGR Voyager Therapeutics	4.0135 of 5 stars	3.6	2.0	4.6	2.4	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$11.75	41.91% Upside
AVBP ArriVent BioPharma	3.14	Buy	$39.29	72.91% Upside
IMTX Immatics	3.20	Buy	$14.67	136.18% Upside
VYGR Voyager Therapeutics	3.13	Buy	$13.39	315.84% Upside

Current Analyst Ratings Breakdown

Latest VYGR, AMLX, AVBP, and IMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	AMLX Amylyx Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$10.00
7/10/2025	AVBP ArriVent BioPharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$33.00
6/24/2025	AMLX Amylyx Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$17.00
6/24/2025	AVBP ArriVent BioPharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$39.00 ➝ $44.00
6/24/2025	AVBP ArriVent BioPharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
6/17/2025	AMLX Amylyx Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
5/30/2025	AMLX Amylyx Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/28/2025	IMTX Immatics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
5/20/2025	AVBP ArriVent BioPharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	-$1.27M	-580.26	N/A	N/A	$2.40 per share	3.45
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$7.65 per share	N/A
IMTX Immatics	$168.65M	4.48	$0.25 per share	24.39	$5.12 per share	1.21
VYGR Voyager Therapeutics	$80M	2.23	N/A	N/A	$5.49 per share	0.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$301.74M	-$3.11	N/A	N/A	N/A	N/A	-77.21%	-63.84%	8/6/2025 (Estimated)
AVBP ArriVent BioPharma	-$80.49M	-$3.77	N/A	N/A	N/A	N/A	-49.21%	-46.61%	8/13/2025 (Estimated)
IMTX Immatics	$16.47M	-$0.17	N/A	N/A	N/A	-14.73%	-4.52%	-3.34%	8/12/2025 (Estimated)
VYGR Voyager Therapeutics	-$65M	-$1.46	N/A	N/A	N/A	-126.49%	-27.36%	-21.06%	8/5/2025 (Estimated)

Latest VYGR, AMLX, AVBP, and IMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AMLX Amylyx Pharmaceuticals	-$0.43	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	AVBP ArriVent BioPharma	-$0.70	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q1 2025	IMTX Immatics	-$0.38	N/A	N/A	N/A	$13.05 million	N/A
8/5/2025	Q2 2025	VYGR Voyager Therapeutics	-$0.48	N/A	N/A	N/A	$9.50 million	N/A
5/13/2025	Q1 2025	IMTX Immatics	-$0.39	-$0.35	+$0.04	-$0.35	$14.92 million	$20.12 million
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/8/2025	Q1 2025	AMLX Amylyx Pharmaceuticals	-$0.45	-$0.42	+$0.03	-$0.42	N/A	N/A
5/6/2025	Q1 2025	VYGR Voyager Therapeutics	-$0.35	-$0.53	-$0.18	-$0.53	$13.55 million	$6.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	$1.02	12.27%	N/A	N/A	N/A
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.05	12.05
AVBP ArriVent BioPharma	N/A	14.34	14.34
IMTX Immatics	N/A	10.28	10.28
VYGR Voyager Therapeutics	N/A	6.10	6.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
AVBP ArriVent BioPharma	9.48%
IMTX Immatics	64.41%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	11.70%
AVBP ArriVent BioPharma	18.58%
IMTX Immatics	3.30%
VYGR Voyager Therapeutics	6.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.14 million	78.71 million	Optionable
AVBP ArriVent BioPharma	40	34.21 million	27.86 million	N/A
IMTX Immatics	260	121.55 million	117.54 million	Optionable
VYGR Voyager Therapeutics	100	55.34 million	51.80 million	Optionable

VYGR, AMLX, AVBP, and IMTX Headlines

Recent News About These Companies

Looking Beyond Voyager 1 And 2

July 17 at 9:27 AM | msn.com

Robert Beltran on Star Trek: I “Risked being fired” Because I Didn’t Like What Was Happening in the Last 3 Years of Voyager

July 16 at 6:25 PM | fandomwire.comF

Uranus Heat Readings Contradict 40-Year-Old Voyager 2 Results

July 16 at 6:25 PM | msn.com

Voyager Therapeutics, Inc.: Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

July 16 at 6:25 PM | finanznachrichten.de

Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

July 16 at 7:00 AM | globenewswire.com

Moon + Bird acquires Alastair Chisholm's book about NASA’s Voyager 1

July 15 at 2:13 PM | thebookseller.comT

Embark On a Summer Adventure Abroad Star Voyager Cruise to Naha, Sanya and More

July 14, 2025 | prestigeonline.comP

Voyager’s Tim Russ Doesn’t Think a Black Vulcan Is a Feat for Star Trek

July 14, 2025 | fandomwire.comF

UK awards AirTanker network node upgrade for Voyager

July 11, 2025 | janes.comJ

Voyager 1 & 2 Could Be Detected From Almost A Light-Year Away With Our Current Technology

July 10, 2025 | msn.com

Brokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) Price Target at $13.39

July 8, 2025 | americanbankingnews.com

RNLI thanks Condor Voyager for helping save French yacht crew in 'challenging conditions'

July 7, 2025 | itv.comI

Atlas Announces New Canadian Arctic Expedition Aboard World Voyager

July 6, 2025 | cruiseindustrynews.comC

With Alipay+ Voyager, Ant International provides an AI travel assistant in Asian E-Wallets

July 5, 2025 | travelmole.comT

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of "Buy" from Brokerages

July 5, 2025 | marketbeat.com

Ant International launches Alipay+ Voyager, an AI-powered travel assistant inside e-wallets

July 3, 2025 | walastech.comW

VYGR Voyager Therapeutics, Inc. - Seeking Alpha

June 25, 2025 | seekingalpha.com

Major Security Breach at RAF Brize Norton Sees Protesters Spray Voyager Aircraft With Paint

June 20, 2025 | theaviationist.comT

Protesters Vandalize RAF Voyager Tankers In Palestine Protest

June 20, 2025 | aviationweek.comA

Voyager Technologies Soars with IPO Success

June 14, 2025 | devdiscourse.comD

Space Tech Ventures Surge: Voyager's IPO Success and Starlink's Swiss Expansion

June 12, 2025 | devdiscourse.comD

New MarketBeat Followers Over Time

Media Sentiment Over Time

VYGR, AMLX, AVBP, and IMTX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$8.28 -0.15 (-1.78%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$8.18 -0.10 (-1.27%)

As of 07/17/2025 07:04 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

ArriVent BioPharma NASDAQ:AVBP

$22.72 +0.82 (+3.74%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$22.64 -0.08 (-0.37%)

As of 07/17/2025 07:40 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Immatics NASDAQ:IMTX

$6.21 +0.08 (+1.31%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$6.22 +0.00 (+0.08%)

As of 07/17/2025 07:48 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Voyager Therapeutics NASDAQ:VYGR

$3.22 -0.05 (-1.53%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$3.22 0.00 (-0.12%)

As of 07/17/2025 07:50 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time